Shorter regimens for tuberculosis infection (TB) treatment of children are associated with increased completion rates and fewer adverse events than the traditional treatment of 9 months of daily isoniazid (9H), a recent study found. The retrospective cohort study included children aged 0 to 18 years from 2014 to 2017 and compared the frequency of completion and adverse events in children receiving 3 months of once-weekly isoniazid and rifapentine (3HP), 4 months of daily rifampin (4R), and 9H. Among the details:
- TB infection treatment was started in 667 children: 283 (42.4%) 3HP, 252 (37.8%) 9H, and 132 (19.8%) 4R.
- Only 52% of children receiving 9H via self-administered therapy (SAT) completed therapy.
- The highest completion rates were seen with 3HP (96.8%) and the lowest with 9H under SAT (52.6%)
- Adverse events were more common in the 9H group.
Cruz AT, Starke JR. Completion rate and safety of tuberculosis infection treatment with shorter regimens. [Published online ahead of print January 23, 2018]. Pediatrics. doi:10.1542/peds.2017-2838.
It is difficult to take medicine, especially when you feel well and the medications are for prevention of future morbidity. Standard therapy for the treatment of latent TB is a 9-month regimen of isoniazid. Even though the 9-month regimen is effective at decreasing the likelihood of developing active TB, this study and others show only about 50% of people complete a 9-month regimen of INH. As former Surgeon General C. Everett Koop once said, “Medicines don’t work in people who don’t take them.” The study above shows that a 3-month regimen of once-weekly isoniazid and rifapentine has much higher rate of completion. — Neil Skolnik, MD
This Week's Must Reads
TNF inhibitor prices rose despite increased drug class competition, San-Juan-Rodriguez A et al. JAMA Intern Med. 2019 Feb 18. doi: 10.1001/jamainternmed.2018.7656
List of medications linked to drug-induced lupus expands, Arnaud L et al. Ann Rheum Dis. 2019 Feb 4. doi: 10.1136/annrheumdis-2018-214598
HCV-infected patients in the ED should be tested for advanced liver fibrosis, Yu-Hsiang Hsieh Y-H. Am J Emerg Med. 2019;37:286-90
Must Reads in Pulmonology
Physician Care for Patients with COPD, CHEST; ePub 2019 Jan 18; Cho, Mecredy, et al
Venous Thromboembolism Risk in US Hospitals, Am J Med; ePub 2019 Jan 16; Huang, et al
Prescribed Opioids & Risk of CAP in Patients with HIV, JAMA Intern Med; 2019 Jan 7; Edelman, et al
HRRP & Patient Mortality in HF, AMI & Pneumonia, JAMA; 2018 Dec 25; Wadhera, et al
COPD in HF Patients & Risk of Hospitalization, JAMA Netw Open; 2018 Dec 14; Lawson, et al